CD8

[Nature Reviews Immunology] Scientists discuss novel latency-reversing agents targeting DCs as well as DC-based strategies to enhance the clearance of infected cells by CD8+ T cells and strategies to improve the killing activity of natural killer cells.

[Frontiers in Immunology] The authors explored the combination between zeste homolog 2 (EZH2) inhibitor and an agonist antibody targeting the T cell costimulatory receptor 4-1BB.

[Journal of Immunology] Through the engineering of an HLA-DR1 chimeric Ag receptor (CAR), the authors produced CD8+ CAR T cells that target CD4+ T cells in an Ag-specific manner and tested their ability to inhibit the development of autoimmune arthritis in a mouse model.

[Journal of Clinical Investigation] Using barcoded pMHC multimers, scientists provided a comprehensive mapping of CD8+ T cells recognizing neoepitopes in Tumor-Infiltrating Lymphocyte infusion products and blood samples from 26 metastatic mela-noma patients who received adoptive cell therapy.

[Trends in Cancer] Research on CD8+ T cell-dependent antitumor immunity has classically focused on its role in the primary tumor.

[Cancer Immunology Research] The authors showed that expression of the axon guidance molecule PlexinA4 in cytotoxic T cell, especially in effector/memory CD8+ T cells, was induced upon T cell activation, sustained in the circulation, but reduced when entering the tumor bed.